Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Strengths
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Predictions on business development from analysts polled by Thomson-Reuters are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • The group usually releases upbeat results with huge surprise rates.
  • The stock is in a well-established, long-term rising trend above the technical support level at 167.29 USD
Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • According to Thomson-Reuters' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
AMGEN25.17%132 728
JOHNSON & JOHNSON18.42%366 178
NOVARTIS13.23%225 160
ROCHE HOLDING LTD.5.20%216 764
PFIZER11.88%216 409
MERCK AND COMPANY7.68%172 887
SANOFI8.71%124 781
BAYER19.19%115 485
BRISTOL-MYERS SQUIBB COMPAN..11.72%107 071
CELGENE CORPORATION17.89%106 760
GLAXOSMITHKLINE-2.94%99 045
ELI LILLY AND COMPANY17.68%95 291
ABBOTT LABORATORIES42.28%94 951
NOVO NORDISK A/S16.92%92 820
ASTRAZENECA15.54%86 062
ALLERGAN PLC-2.14%68 707
More Results
Financials ($)
Sales 2017 22 854 M
EBIT 2017 11 807 M
Net income 2017 8 130 M
Finance 2017 4 380 M
Yield 2017 2,47%
P/E ratio 2017 16,43
P/E ratio 2018 16,08
EV / Sales 2017 5,62x
EV / Sales 2018 5,48x
Capitalization 133 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart AMGEN
Duration : Period : Day
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Duration : Period : Week
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders